Natco Pharma releases Hepatitis C drug in India
03 July 2018 | News
The product is a generic fixed dose combination of Sofosbuvir 400 mg and Daclatasvir 60mg tablets.
Image credit- npr.org
Fixed dose combination of Sofosbuvir-Daclatasvir tablets for the treatment of Hepatitis C under the brand name Hepcinat Plus, has been launched by Natco Pharma in India.
The product is a generic fixed dose combination of Sofosbuvir 400 mg and Daclatasvir 60mg tablets, used for the treatment of patients with chronic Hepatitis C virus (HCV) infection
The company has launched the drug at a maximum retail price of Rs 17,500 for a bottle of 28 tablets.
